News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,274 Results
Type
Article (39966)
Company Profile (248)
Press Release (664060)
Multimedia
Podcasts (57)
Webinars (14)
Section
Business (204265)
Career Advice (2011)
Deals (35450)
Drug Delivery (95)
Drug Development (81123)
Employer Resources (172)
FDA (16239)
Job Trends (14884)
News (345456)
Policy (32593)
Tag
Academia (2556)
Accelerated approval (7)
Adcomms (22)
Allergies (95)
Alliances (49568)
ALS (106)
Alzheimer's disease (1429)
Antibody-drug conjugate (ADC) (150)
Approvals (16232)
Artificial intelligence (302)
Autoimmune disease (27)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (115)
Biotechnology (175)
Bladder cancer (90)
Brain cancer (33)
Breast cancer (356)
Cancer (2793)
Cardiovascular disease (207)
Career advice (1681)
Career pathing (30)
CAR-T (181)
CDC (30)
Cell therapy (488)
Cervical cancer (22)
Clinical research (66757)
Collaboration (990)
Company closure (3)
Compensation (659)
Complete response letters (19)
COVID-19 (2620)
CRISPR (55)
C-suite (307)
Cystic fibrosis (110)
Data (2900)
Decentralized trials (2)
Denatured (20)
Depression (56)
Diabetes (342)
Diagnostics (6418)
Digital health (23)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (133)
Drug pricing (119)
Drug shortages (27)
Duchenne muscular dystrophy (122)
Earnings (87399)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113668)
Executive appointments (844)
FDA (17826)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (909)
Gene editing (128)
Generative AI (22)
Gene therapy (367)
GLP-1 (773)
Government (4492)
Grass and pollen (4)
Guidances (180)
Healthcare (18838)
Huntington's disease (30)
IgA nephropathy (38)
Immunology and inflammation (139)
Immuno-oncology (7)
Indications (39)
Infectious disease (2784)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (59)
Intellectual property (114)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (488)
Leadership (18)
Legal (7926)
Liver cancer (78)
Lung cancer (393)
Lymphoma (203)
Machine learning (9)
Management (58)
Manufacturing (373)
MASH (87)
Medical device (13441)
Medtech (13446)
Mergers & acquisitions (19566)
Metabolic disorders (831)
Multiple sclerosis (96)
NASH (16)
Neurodegenerative disease (111)
Neuropsychiatric disorders (31)
Neuroscience (2087)
NextGen: Class of 2025 (6516)
Non-profit (4488)
Now hiring (47)
Obesity (420)
Opinion (216)
Ovarian cancer (99)
Pain (102)
Pancreatic cancer (117)
Parkinson's disease (185)
Partnered (22)
Patents (287)
Patient recruitment (152)
Peanut (50)
People (57644)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20803)
Phase II (29405)
Phase III (21884)
Pipeline (1588)
Policy (194)
Postmarket research (2563)
Preclinical (8853)
Press Release (64)
Prostate cancer (135)
Psychedelics (34)
Radiopharmaceuticals (252)
Rare diseases (448)
Real estate (5917)
Recruiting (66)
Regulatory (22554)
Reports (50)
Research institute (2324)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (48)
Schizophrenia (81)
Series A (150)
Series B (103)
Service/supplier (11)
Sickle cell disease (59)
Special edition (18)
Spinal muscular atrophy (147)
Sponsored (31)
Startups (3585)
State (2)
Stomach cancer (13)
Supply chain (73)
Tariffs (56)
The Weekly (35)
Vaccines (762)
Venture capital (52)
Weight loss (253)
Women's health (44)
Worklife (16)
Date
Today (80)
Last 7 days (407)
Last 30 days (2166)
Last 365 days (31204)
2025 (16170)
2024 (35219)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38174)
Australia (6229)
California (7317)
Canada (2302)
China (662)
Colorado (312)
Connecticut (314)
Delaware (189)
Europe (82026)
Florida (1101)
Georgia (244)
Hawaii (1)
Idaho (59)
Illinois (628)
India (26)
Indiana (357)
Iowa (16)
Japan (221)
Kansas (108)
Kentucky (28)
Louisiana (14)
Maine (64)
Maryland (1012)
Massachusetts (5428)
Michigan (244)
Minnesota (445)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2039)
New Mexico (28)
New York (2059)
North Carolina (1062)
North Dakota (8)
Northern California (3217)
Ohio (232)
Oklahoma (16)
Oregon (34)
Pennsylvania (1591)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (33)
South Dakota (1)
Southern California (2722)
Tennessee (124)
Texas (1098)
United States (27141)
Utah (217)
Virginia (181)
Washington D.C. (72)
Washington State (623)
West Virginia (4)
Wisconsin (63)
704,274 Results for "alumis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Major Shareholder Opposes Acelyrin’s Merger With Alumis, Prefers Wind-Down
It’s been a fraught road for the proposed merger between Acelyrin and Alumis, with Tang Capital’s Concentra Biosciences in February threatening to upend the deal with a proposed $3-per-share acquisition of Acelyrin.
April 30, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.
March 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alumis Completes Merger with ACELYRIN
May 21, 2025
·
4 min read
Mergers & acquisitions
Concentra Offers to Buy Acelyrin, Endangering Proposed Merger With Alumis
Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding the combined company over until 2027.
February 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alumis Stockholders Approve Merger with ACELYRIN
May 14, 2025
·
10 min read
Mergers & acquisitions
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases
Alumis held its initial public offering in June last year, while Acelyrin debuted on the Nasdaq in mid-2023.
February 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alumis to Present at the 2025 Jefferies Global Healthcare Investor Conference
May 30, 2025
·
1 min read
Press Releases
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
·
15 min read
Press Releases
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 2, 2025
·
12 min read
Press Releases
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 14, 2025
·
18 min read
1 of 70,428
Next
